The TNM classification of malignant tumours is a mainstay tool in clinical practice and
research for prognostic assessment of patients, treatment allocation and trial enrolment, as …

The diagnosis and management of pancreatic neuroendocrine neoplasms (NENs) have
evolved significantly in recent years. There are several diagnostic and therapeutic …

Objective: The aim of this study was to evaluate and validate the proposed 8th edition
American Joint Committee on Cancer (AJCC) system for T and N staging of pancreatic …

Abstract An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus
meeting of expert panellists was convened on 15 January 2014 to review current evidence …

Background The 8th edition of the AJCC staging system for pancreatic cancer incorporated
several significant changes. This study sought to evaluate this staging system and assess its …

Background: There are no established guidelines for pathologic diagnosis/reporting of
intraductal papillary mucinous neoplasms (IPMNs). Design: An international …

In the past decade, the clinico-pathologic characteristics of neuroendocrine tumors (NETs) in
the pancreas have been further elucidated. Previously termed “islet cell tumors/carcinomas” …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive gastrointestinal malignancy
with a poor 5-year survival rate. Its high mortality rate is attributed to its aggressive biology …

Background: CD44 is a potentially interesting prognostic marker and therapeutic target in
pancreatic cancer. The expression of CD44 has been reported to correlate with poor …

Context.—Cancer staging provides critical information for patients and treating physicians to
battle against cancer, predict prognosis, and guide treatment decisions. The American Joint …